Study S001807

A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy

ClinicalTrials.gov record Statistical Analysis Plan (PDF)Study Protocol (PDF)

Registration

Registration: NCT02973100
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 318
Start: 2016-12
Primary completion: 2017-07-15
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes
Interventions: DRUG:Dulaglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:H9X-MC-GBGJ; EUDRACT_NUMBER:2016-002494-34; NIH:2016

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 18]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.